Turkistani Yosra
Department of Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Front Cardiovasc Med. 2025 Apr 24;12:1535134. doi: 10.3389/fcvm.2025.1535134. eCollection 2025.
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are novel agents with proven cardiovascular (CV) benefits. GLP-1 RAs have been used for diabetes and found to improve CV outcomes in diabetic and nondiabetic patients. They are authorized for treating obesity. Our narrative review discussed the CV benefits of GLP-1 RAs in terms of controlling CV risk factors and improving CV outcomes in diabetic and nondiabetic patients regardless of their CV history, and the CV perspectives related to their use in clinical practice.
Literature was searched with no limits on date or language, using various combinations of keywords. Data on the CV benefits of GLP-1 RAs and their use in clinical practice were summarized.
Several studies have discussed the CV beneficial effects of GLP-1 RAs in terms of reducing blood pressure, lipid levels, body weight, risk for arrhythmias, reducing the risk of major adverse CV events, and hospital admission for heart failure.
The cardioprotective effects and low risk of hypoglycemia of GLP-1 RAs make them preferred agents in any multidisciplinary approach aiming to reduce CV disease burden and improve prognosis. Cardiologists are encouraged to strongly consider the CV benefits of GLP-1 RAs in their risk-reduction strategies.
胰高血糖素样肽-1受体激动剂（GLP-1 RA）是已证实具有心血管（CV）益处的新型药物。GLP-1 RA已用于治疗糖尿病，并被发现可改善糖尿病患者和非糖尿病患者的心血管结局。它们已被批准用于治疗肥胖症。我们的叙述性综述讨论了GLP-1 RA在控制心血管危险因素以及改善糖尿病和非糖尿病患者（无论其心血管病史如何）的心血管结局方面的心血管益处，以及与它们在临床实践中的使用相关的心血管方面的观点。
使用各种关键词组合对文献进行检索，不限日期和语言。总结了GLP-1 RA的心血管益处及其在临床实践中的应用数据。
多项研究讨论了GLP-1 RA在降低血压、血脂水平、体重、心律失常风险、降低主要不良心血管事件风险以及因心力衰竭住院方面的心血管有益作用。
GLP-1 RA的心脏保护作用和低血糖风险低，使其成为任何旨在减轻心血管疾病负担和改善预后的多学科方法中的首选药物。鼓励心脏病专家在其降低风险策略中充分考虑GLP-1 RA的心血管益处。
